Peer-influenced content. Sources you trust. No registration required. This is HCN.

DocWire NewsA Promising First-line Treatment for Unresectable Hepatocellular Carcinoma

Study Reveals Tislelizumab’s Efficacy and Safety in uHCC Treatment

A recent study published in JAMA Oncology has shed light on the potential of tislelizumab as a first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC). The study, known as RATIONALE-301, aimed to assess the efficacy and safety of tislelizumab in comparison to sorafenib tosylate.

HCN Medical Memo
This study reinforces the potential of tislelizumab as a first-line treatment option for patients with unresectable HCC. Healthcare professionals should consider these findings when making treatment decisions for their patients with uHCC in the future.

Key Points

  • The RATIONALE-301 study was an open-label, global, randomized, multiregional, phase 3 trial.
  • It enrolled 674 systemic therapy-naive adults with histologically confirmed uHCC.
  • Participants were randomized to receive either tislelizumab 200 mg intravenously every 3 weeks or sorafenib tosylate 400 mg orally twice daily.
  • The primary endpoint was overall survival (OS), with secondary outcomes including objective response rate (ORR), progression-free survival, duration of response, and safety.
  • Tislelizumab met the primary endpoint of OS noninferiority versus sorafenib in the intention-to-treat population.
  • Tislelizumab demonstrated a higher ORR and a higher median duration of response.

Hepatocellular carcinoma is the most common type of primary liver cancer, accounting for about 75% of all liver cancers.

More on Liver Cancer

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form